News · Longevity & Aging
One compound stood out in a blood scan of midlife brains
A Nature Aging study measured 991 blood metabolites in 1,082 middle-aged adults and found ergothioneine, a mushroom-derived compound, had the strongest link to cognition.
Based on a peer-reviewed study in Nature Aging
- Researchers measured 991 blood metabolites against cognition and brain scans in 1,082 dementia-free middle-aged people from the Rotterdam Study, publishing in Nature Aging.
- 22 metabolites were associated with MRI measures, and 14 showed replicated associations with cognition in two independent cohorts of older adults.
- Ergothioneine, a compound obtained mainly from mushrooms, showed the largest effect of any metabolite.
- The metabolite signature of cognition mirrored the signature of later Alzheimer's disease, suggesting these markers track a real trajectory.
- Lifestyle, clinical variables and medication were the strongest determinants of these metabolites, explaining up to 28.6% of their variance.
- Antacid use was associated with worse cognition and lower ergothioneine, and lower ergothioneine accounted for 31.5% of that link.
- This is observational and cross-sectional for the main analysis. Nobody was given ergothioneine, and no supplement was tested.
Measure a thousand chemicals in the blood of a thousand middle-aged people, and see which ones track with how their brains are doing. A study in Nature Aging did that. One compound came out on top by a clear margin: a substance most people get, if at all, from mushrooms.
The researchers examined the relation of 991 blood metabolites with cognition and magnetic resonance imaging measures in 1,082 dementia-free middle-aged participants. Ergothioneine exhibited the largest effect.
Why midlife, and why blood
Alzheimer’s disease is increasingly understood as something that begins decades before diagnosis. That makes middle age the window to watch, and cheap blood markers the thing to measure.
The rationale the authors give is that metabolic alterations are increasingly implicated in neurological disorders, including Alzheimer’s disease, highlighting the relevance of the peripheral metabolome, shaped by genetic and environmental exposures, for brain health.
Until now most of this work had looked at older adults already declining. Looking earlier changes what the markers might be for.
The design, and the part that earns trust
The main analysis drew on the population-based Rotterdam Study, relating metabolites to both cognitive testing and brain imaging.
Screening 991 compounds at once will throw up false positives, so the next step is the one that matters. Cognition-associated metabolites were replicated in two independent cohorts of older adults and tested for associations with incident Alzheimer’s disease longitudinally in one cohort.
Twenty-two metabolites were associated with MRI measures. Better still, the metabolite signature of cognition mirrored that of incident Alzheimer’s disease. The same chemical pattern that tracked thinking in midlife also tracked who later got the disease.
The compound that led
Ergothioneine is not a household name, though it has a small research following. Humans cannot synthesize it and must eat it, overwhelmingly from mushrooms. The body maintains a dedicated transporter for it. That is the kind of detail that makes biologists suspect something matters.
Fourteen metabolites showed replicated associations with cognition, with ergothioneine exhibiting the largest effect.
What shapes these markers
The study’s second half asks where the metabolites come from, and the answer is not mainly your parents. Lifestyle, clinical variables and medication were the strongest determinants of cognition-associated and MRI-associated metabolites, explaining up to 28.6% of their variance.
One specific thread stands out. Antacid use was associated with worse cognition and lower ergothioneine levels, which mediated 31.5% of the negative medication effect.
Stomach acid assists absorption of the compound, so a drug that suppresses acid plausibly lowers it. That is a coherent chain, and it is still a statistical mediation in observational data. Nobody should stop a prescribed medicine on the strength of it.
The distance to advice
This is observational, and the core analysis is a snapshot. High ergothioneine may mark people who eat well, or who absorb nutrients well, or who are simply healthier for reasons the model missed.
Critically, no one was given anything. Measuring a compound in blood is not the same as testing whether raising it helps. No trial has done that.
What the study offers is a well-replicated target and an unusually specific hypothesis, which the authors themselves flag as suggesting implications for AD prevention.
Mushrooms are good food. Whether they are brain medicine is now a question precise enough for someone to run a trial on, which is a better position than the field was in last year.
People also ask
What is ergothioneine?
An amino acid derivative that humans cannot make and must obtain from food, principally mushrooms, with smaller amounts in beans, oats and organ meats. The body has a dedicated transporter for it, which is unusual and has led some researchers to argue it functions as a vitamin. It accumulates in tissues under oxidative stress, including the brain, and has been linked to cognition in earlier observational work.
Should I eat more mushrooms, or take a supplement?
Mushrooms are a reasonable food regardless, and nothing here argues against them. But this study measured ergothioneine already circulating in people's blood; it did not give anyone any. An association between a blood level and cognition does not establish that raising the level improves anything, and no supplement trial supports that yet. Treat the mushroom angle as a hypothesis rather than a prescription.
Why does the antacid finding matter?
It is the most concrete thread in the paper. Antacid use was associated with worse cognition and lower ergothioneine levels, and the lower ergothioneine statistically accounted for 31.5% of that negative medication effect. Stomach acid helps absorb the compound, so the mechanism is plausible. It is a mediation analysis in observational data, not proof, and nobody should stop prescribed medication on the strength of it.
How much can 991 metabolites in 1,082 people really show?
Measuring that many markers invites false positives, which is why the replication step matters most. Fourteen of the cognition-associated metabolites held up in two independent cohorts of older adults, and the overall signature matched that of people who went on to develop Alzheimer's disease. That combination is considerably stronger than a single-cohort screen.
Is your metabolome fixed by your genes?
Largely not, which is the encouraging part. Lifestyle, clinical variables and medication were the strongest determinants of the cognition- and MRI-associated metabolites, explaining up to 28.6% of their variance. Genetics and gut bacteria contributed less. What circulates in your blood at 50 is shaped substantially by how you have lived and what you take.